Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Christian Bailly, Xavier Thuru, Bruno Quesnel
NAR Cancer (2020) Vol. 2, Iss. 1
Open Access | Times Cited: 201

Showing 1-25 of 201 citing articles:

Systemic immunity in cancer
Kamir J. Hiam-Galvez, Breanna M. Allen, Matthew H. Spitzer
Nature reviews. Cancer (2021) Vol. 21, Iss. 6, pp. 345-359
Open Access | Times Cited: 976
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Mateusz Kciuk, Adrianna Gielecińska, Somdutt Mujwar, et al.
Cells (2023) Vol. 12, Iss. 4, pp. 659-659
Open Access | Times Cited: 308
Chemotherapy: a double-edged sword in cancer treatment
Nafiseh Behranvand, Farzad Nasri, Reza Zolfaghari Emameh, et al.
Cancer Immunology Immunotherapy (2021) Vol. 71, Iss. 3, pp. 507-526
Open Access | Times Cited: 220
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack, Andrew X. Zhu, Yulei Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 203
Artificial intelligence aids in development of nanomedicines for cancer management
Ping Tan, Xiaoting Chen, Hu Zhang, et al.
Seminars in Cancer Biology (2023) Vol. 89, pp. 61-75
Closed Access | Times Cited: 146
Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application
Hongli Gao, Jianqiao Yin, Ce Ji, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 50
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Y.L. Verschoor, Joris van de Haar, José G. van den Berg, et al.
Nature Medicine (2024) Vol. 30, Iss. 2, pp. 519-530
Open Access | Times Cited: 49
The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy
Wen Deng, Haojie Shang, Yonghua Tong, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 24
Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations
Yosi Gilad, Gary Gellerman, David M. Lonard, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 669-669
Open Access | Times Cited: 102
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
Christian Bailly, Xavier Thuru, Bruno Quesnel
Cancers (2021) Vol. 13, Iss. 12, pp. 3034-3034
Open Access | Times Cited: 97
Regulation of PD-L1 expression on cancer cells with ROS-modulating drugs
Christian Bailly
Life Sciences (2020) Vol. 246, pp. 117403-117403
Closed Access | Times Cited: 80
Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine
Afshin Derakhshani, Shahryar Hashemzadeh, Zahra Asadzadeh, et al.
Cancers (2021) Vol. 13, Iss. 10, pp. 2414-2414
Open Access | Times Cited: 72
Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
Dobrina Tsvetkova, Stefka Ivanova
Molecules (2022) Vol. 27, Iss. 8, pp. 2466-2466
Open Access | Times Cited: 66
Strategies to tackle RAS-mutated metastatic colorectal cancer
Giorgio Patelli, Federica Tosi, Alessio Amatu, et al.
ESMO Open (2021) Vol. 6, Iss. 3, pp. 100156-100156
Open Access | Times Cited: 58
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review
Ezgi B. Ulas, Chris Dickhoff, Famke L. Schneiders, et al.
ESMO Open (2021) Vol. 6, Iss. 5, pp. 100244-100244
Open Access | Times Cited: 58
Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer
Yujie Zhao, Xu Liu, Xinyu Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 55
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Daniel R. Principe, Suneel D. Kamath, Murray Korc, et al.
Pharmacology & Therapeutics (2022) Vol. 236, pp. 108111-108111
Open Access | Times Cited: 45
Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis
Yujia Chen, Jianjun Qin, Yajing Wu, et al.
International Journal of Surgery (2023)
Open Access | Times Cited: 29
VISTA expression and patient selection for immune-based anticancer therapy
Alexander S. Martin, Michael Molloy, Andrey Ugolkov, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
PD-1/PD-L1 and DNA Damage Response in Cancer
Mateusz Kciuk, Damian Kołat, Żaneta Kałuzińska‐Kołat, et al.
Cells (2023) Vol. 12, Iss. 4, pp. 530-530
Open Access | Times Cited: 23
Investigation of the impact of copper nanoparticles coated with ocimum bassilicum at chemoradiotherapy of colon carcinoma
Farshad Seyed Nejad, Mostafa Alizade‐Harakiyan, Mehdi Haghi, et al.
Biochemistry and Biophysics Reports (2024) Vol. 39, pp. 101780-101780
Open Access | Times Cited: 10
Recent progress in stimuli-responsive nanosystems for inducing immunogenic cell death
Asmita Banstola, Kishwor Poudel, Jong Oh Kim, et al.
Journal of Controlled Release (2021) Vol. 337, pp. 505-520
Closed Access | Times Cited: 52
Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
Juwon Lee, Youngjin Han, Wenyu Wang, et al.
Biomolecules (2021) Vol. 11, Iss. 8, pp. 1107-1107
Open Access | Times Cited: 48
Synergy of nanodiamond–doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells
Hua‐Zhen Xu, Tongfei Li, Chao Wang, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 43
A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects
Ho Jin Lee, Hyeyoung Min, Young-Sik Yong, et al.
Theranostics (2021) Vol. 12, Iss. 1, pp. 105-125
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top